openPR Logo
Press release

Global Anti-migraine Drugs Market to be Driven by Increasing Awareness Regarding Availability of Effective Anti-migraine Drugs

11-21-2016 02:43 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Global Anti-migraine Drugs Market to be Driven by Increasing

A new market research study by Transparency Market Research provides a detailed analysis of the global market for anti-migraine drugs, including the major growth factors, barriers, product segmentation, current trends, major geographical segments, and competitive landscape. The research report, titled “Anti-Migraine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” also presents the historical statistics and forecast figures to the readers, with the help of infographics, graphs, charts, and tables.

Download Exclusive Sample of this Report: http://bit.ly/1qCHYFv

The research study has included recommendations given by industry experts, which are expected to help major players and decision-makers design their strategies and policies in an effective manner. Furthermore, the study has segmented the global market for anti-migraine drugs on the basis of type, technology, and geography. The estimated statistics and share of each segment are presented in the scope of the research report.

Anti-migraine drugs refer to therapeutic agents that are to be used against migraine headaches. These drugs help in reducing the intensity of migraine pain. A migraine is more common in women compared to men, due to the fluctuations that are caused due to the changing hormone levels. The increasing number of migraine sufferers across the globe is one of the major factors responsible for the rapid growth of the global market for anti-migraine drugs. Some of the major anti-migraine drugs that are used widely are Zolmitriptan, Sumatriptan, and others.

Migraine headaches cause great distress to the patient and further add to their overall healthcare expenditure. The major types of migraines are common and classic. Patients suffering from a common migraine feel sudden headaches on either one or both sides of the head. On the other hand, patients suffering from classic migraine headaches witness a sudden change in eyesight and many a time experience partial blindness.

The steady rise in the prevalence of migraine worldwide, growing awareness regarding the availability of effective anti-migraine drugs, increasing level of acceptance, and technological developments are some of the key factors that are projected to augment the growth of the global anti-migraine drugs market throughout the forecast period. On the flip side, the emergence of local players, high genericization, and impending patent expiration are the key factors hampering the growth of the market.

Browse Research Report: http://bit.ly/1XGch98

Some of the prominent players operating in the global market for anti-migraine drugs are GlaxoSmithKline plc, Abbott Laboratories, Inc. AstraZeneca plc, Pfizer, Inc., Eisai, Inc., and Eli Lilly and Company. A detailed analysis of the major players, focusing on the product portfolio, business strategies, financial overview, SWOT analysis, and recent developments in the market has been provided in the report.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Anti-migraine Drugs Market to be Driven by Increasing Awareness Regarding Availability of Effective Anti-migraine Drugs here

News-ID: 385217 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Drugs

Global Antithrombotic Drugs Market | Global Antithrombotic Drugs Industry | Glob …
Antithrombotic drugs are special drugs that help to prevent the formation of thrombus or clot. These drugs are used to reduce the formation of blood clots by reducing the capability of body to form a blood clot. Antithrombotic drugs act by preventing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are different types of antithrombotic agents that act by different clotting processes. Arterial & venous
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Epilepsy Drugs Market by Country, Drugs, Company & Forecast
For More Information: https://renub-research.blogspot.com/2019/04/the-factors-that-are-driving-global.html Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types - generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$
Prospect of Global Excipients Market Research Report 2017 with Application inclu …
ResearchMoz added Latest Research Report titled " Global Excipients Market Research Report 2017 " to it's Large Report database. In this report, the global Excipients market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD),
Drugs research: Misuse by shareholders of the drugs industry
A new textbook illustrates the complex and multi-faceted dimensions of evidence building in European drugs research. On one level, the authors have identified practical and philosophical challenges regarding knowledge production including, for example, measurements of the drugs problem; researching the online world; and interpreting on-site drug tests. On another level, the authors have highlighted challenges regarding knowledge production such as the misuse of evidence by knowledge brokers and policymakers.